DK1765289T3 - Sammensætninger og fremgangsmåder til stabilisering af adjuvansformuleringer på lipidbasis under anvendelse af glycolipider - Google Patents

Sammensætninger og fremgangsmåder til stabilisering af adjuvansformuleringer på lipidbasis under anvendelse af glycolipider

Info

Publication number
DK1765289T3
DK1765289T3 DK05756461T DK05756461T DK1765289T3 DK 1765289 T3 DK1765289 T3 DK 1765289T3 DK 05756461 T DK05756461 T DK 05756461T DK 05756461 T DK05756461 T DK 05756461T DK 1765289 T3 DK1765289 T3 DK 1765289T3
Authority
DK
Denmark
Prior art keywords
glycolipids
compositions
methods
based adjuvant
adjuvant formulations
Prior art date
Application number
DK05756461T
Other languages
Danish (da)
English (en)
Inventor
Jesper Davidsen
Ida Rosenkrands
Peter Andersen
Original Assignee
Statens Seruminstitut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34982425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1765289(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Statens Seruminstitut filed Critical Statens Seruminstitut
Application granted granted Critical
Publication of DK1765289T3 publication Critical patent/DK1765289T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
DK05756461T 2004-07-07 2005-07-05 Sammensætninger og fremgangsmåder til stabilisering af adjuvansformuleringer på lipidbasis under anvendelse af glycolipider DK1765289T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200401070 2004-07-07
PCT/DK2005/000467 WO2006002642A2 (en) 2004-07-07 2005-07-05 Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids

Publications (1)

Publication Number Publication Date
DK1765289T3 true DK1765289T3 (da) 2008-12-15

Family

ID=34982425

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05756461T DK1765289T3 (da) 2004-07-07 2005-07-05 Sammensætninger og fremgangsmåder til stabilisering af adjuvansformuleringer på lipidbasis under anvendelse af glycolipider

Country Status (16)

Country Link
EP (1) EP1765289B1 (ko)
JP (1) JP4987704B2 (ko)
KR (1) KR101275837B1 (ko)
CN (1) CN1980638B (ko)
AT (1) ATE406874T1 (ko)
AU (1) AU2005259685B2 (ko)
BR (1) BRPI0512757B8 (ko)
CA (1) CA2572985C (ko)
DE (1) DE602005009535D1 (ko)
DK (1) DK1765289T3 (ko)
ES (1) ES2315880T3 (ko)
PL (1) PL1765289T3 (ko)
PT (1) PT1765289E (ko)
SI (1) SI1765289T1 (ko)
WO (1) WO2006002642A2 (ko)
ZA (1) ZA200701043B (ko)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2402023A1 (en) 2006-06-28 2012-01-04 Statens Serum Institut Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails
CA3144493A1 (en) 2006-10-03 2008-04-10 Arbutus Biopharma Corporation Lipid containing formulations
ES2394729T3 (es) 2007-06-29 2013-02-05 Statens Serum Institut El uso de monomicolil glicerol (MMG) como adyuvante
EP2711020B1 (en) * 2008-05-02 2016-08-10 BliNK Therapeutics Limited Products and methods for stimulating an immune response
JP2012514476A (ja) * 2009-01-08 2012-06-28 アルバート アインシュタイン カレッジ オブ メディシン オブ イェシバ ユニバーシティ，ア ディビジョン オブ イェシバ ユニバーシティ 細胞壁結合セラミド様糖脂質による細菌ワクチンおよびその使用
AU2010270722B2 (en) * 2009-07-06 2015-06-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
RU2603274C2 (ru) * 2010-07-02 2016-11-27 Интервет Интернэшнл Б.В. Вакцина против ehrlichia canis
DK2729127T3 (en) 2011-07-04 2018-08-06 Statens Seruminstitut METHODS FOR LIPOSOMES PREPARATION
JP6182458B2 (ja) * 2011-12-12 2017-08-16 協和発酵キリン株式会社 カチオン性脂質の組み合わせを含有する脂質ナノ粒子
EP2792367A4 (en) 2011-12-12 2015-09-30 Kyowa Hakko Kirin Co Ltd LIPID NANOPARTICLES FOR A DRUG DELIVERY SYSTEM CONTAINING CATIONIC LIPIDS
JP2016175841A (ja) * 2013-08-02 2016-10-06 三郎 斎藤 リポソームと、細胞障害性ｔ細胞活性を誘導するワクチン組成物
CA2924526A1 (en) * 2013-09-19 2015-03-26 Paul Joseph Dominowski Water-in-oil emulsions comprising immunostimulatory oligonucleotides
CN106535933B (zh) * 2014-08-04 2021-09-17 日东电工株式会社 包含核受体配体的免疫诱导促进用组合物以及疫苗药物组合物
PL3325015T3 (pl) * 2015-07-20 2021-10-25 Zoetis Services Llc Liposomowe kompozycje adiuwantowe
CN114657147B (zh) * 2022-01-27 2023-12-01 安徽智飞龙科马生物制药有限公司 一种生物材料的保护剂及其应用
CN115068602B (zh) * 2022-08-22 2022-11-01 北京华诺泰生物医药科技有限公司 一种表面改性氧化铝的复合疫苗佐剂、制备方法及应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108934A (en) * 1983-11-30 1992-04-28 Kabushiki Kaisha Toshiba Quantitative immunoassay utilizing liposomes
JP2714972B2 (ja) * 1988-02-02 1998-02-16 千葉製粉株式会社 リン脂質集合体用修飾剤、リン脂質小胞体用凝集防止剤、リン脂質小胞体用融合防止剤およびリン脂質膜用表面固定化剤
JPH03249561A (ja) * 1990-02-28 1991-11-07 Toshiba Corp 免疫分析試薬
JPH0482824A (ja) * 1990-07-23 1992-03-16 Nippon Oil & Fats Co Ltd リポソーム及び水中油型エマルション
JPH0616688A (ja) * 1992-06-30 1994-01-25 Nippon Oil & Fats Co Ltd 脂肪酸糖エステル
JP3884488B2 (ja) * 1993-03-10 2007-02-21 千葉製粉株式会社 オリゴ糖脂質
JP3329554B2 (ja) * 1993-03-10 2002-09-30 千葉製粉株式会社 乾燥小胞体
US5885613A (en) * 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
JPH0925287A (ja) * 1995-07-13 1997-01-28 Eisai Co Ltd 合成脂質
JPH09110722A (ja) * 1995-10-20 1997-04-28 Toray Ind Inc 抗腫瘍活性物質の腫瘍細胞内導入用イムノリポソーム及びその調製法
US6183774B1 (en) * 1996-01-31 2001-02-06 Collaborative Laboratories, Inc. Stabilizing vitamin A derivatives by encapsulation in lipid vesicles formed with alkylammonium fatty acid salts
US6210707B1 (en) * 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
GB9808268D0 (en) * 1998-04-17 1998-06-17 Imp College Innovations Ltd Compound
GB0007150D0 (en) * 2000-03-24 2000-05-17 Lamellar Therapeutics Limited Immunotherapeutic methods and compositions
IL159334A0 (en) * 2001-06-25 2004-06-01 Yissum Res Dev Co A method for preparation of vesicles loaded with biological material and different uses thereof

Also Published As

Publication number Publication date
ATE406874T1 (de) 2008-09-15
ZA200701043B (en) 2007-12-27
BRPI0512757A (pt) 2008-04-08
EP1765289A2 (en) 2007-03-28
AU2005259685B2 (en) 2010-04-08
BRPI0512757B8 (pt) 2021-05-25
ES2315880T3 (es) 2009-04-01
SI1765289T1 (sl) 2009-02-28
EP1765289B1 (en) 2008-09-03
JP2008505131A (ja) 2008-02-21
CN1980638B (zh) 2011-10-12
KR20070051847A (ko) 2007-05-18
PT1765289E (pt) 2008-12-05
PL1765289T3 (pl) 2009-02-27
CA2572985C (en) 2014-04-22
JP4987704B2 (ja) 2012-07-25
WO2006002642A3 (en) 2006-05-18
DE602005009535D1 (de) 2008-10-16
KR101275837B1 (ko) 2013-06-18
WO2006002642A2 (en) 2006-01-12
BRPI0512757B1 (pt) 2021-04-06
AU2005259685A1 (en) 2006-01-12
CA2572985A1 (en) 2006-01-12
CN1980638A (zh) 2007-06-13

Similar Documents

Publication Publication Date Title
DK1765289T3 (da) Sammensætninger og fremgangsmåder til stabilisering af adjuvansformuleringer på lipidbasis under anvendelse af glycolipider
MX2010001054A (es) Composiciones adyuvantes antigenicas y metodos.
RU2013114392A (ru) Маленькие липосомы для доставки кодирующей иммуноген рнк
DE60039198D1 (de) Adjuvanszusammensetzungen zur Erhöhung der Immunantwort bezüglich Polynukleotid-basierenden Impfstoffen
EP4056198A3 (en) Outer membrane vesicles
EE05633B1 (et) Muundatud vaktsiiniaviirus Ankara (MVA), sellega nakatatud peremeesrakk ning seda sisaldav farmatseutiline kompositsioon, MVA valmistamine ja raviotstarbeline kasutamine
BR112013017382A2 (pt) métodos para preparação de glicoesfingolipídios e usos destes
WO2007024941A3 (en) Polyvalent vaccine
DK1361890T3 (da) Influenzavaccineformuleringer til intradermal indgift
MX2009008928A (es) Composiciones que comprenden conjugados de polisacaridos y su uso como vacunas.
AU2005332599A8 (en) Polyinosinic acid-polycytidylic acid-based adjuvant
DK1748791T3 (da) Neisseria Meningitidis IgtB LOS som hjælpestof
PT1951300E (pt) Modificação do equilíbrio de th1/th2 em vacinas da influenza fragmentadas com adjuvantes
WO2002087494A3 (en) Novel vaccine
MX2020001385A (es) Composiciones que comprenden construcciones geneticas y vacunas de il-12 mejoradas, agentes inmunoterapeuticos y metodos para su uso.
WO2010019262A3 (en) Polyvalent vaccine
WO2008148057A3 (en) Cationic lipids compositions and methods for enhancing immune responses to vaccines
MX2009004862A (es) Estabilizacion de vacunas por liofilizacion.
TW200510538A (en) Functionally reconstituted viral membranes containing adjuvant
WO2010053610A3 (en) Stable anthrax vaccine formulations
PH12018500458A1 (en) Vlp stabilized vaccine compositions
DE60336588D1 (de) Verbesserte anthraximpfstoffe und abgabeverfahren
WO2011074006A3 (en) Vaccine composition
WO2023235660A3 (en) Flavivirus immunogens and vaccine compositions and methods of using the same
NO20045587L (no) Liposom vaksineformulering for finne-fisk